Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 33 | 2023 | 5709 | 3.030 |
Why?
|
Skin Neoplasms | 15 | 2023 | 5821 | 1.650 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2021 | 561 | 0.810 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2019 | 259 | 0.570 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5305 | 0.500 |
Why?
|
Piperazines | 3 | 2021 | 2523 | 0.450 |
Why?
|
Mucous Membrane | 4 | 2021 | 659 | 0.440 |
Why?
|
Pyridines | 4 | 2022 | 2875 | 0.430 |
Why?
|
Telomerase | 1 | 2017 | 745 | 0.400 |
Why?
|
Glucocorticoids | 1 | 2021 | 2161 | 0.390 |
Why?
|
Interferon-gamma | 2 | 2019 | 3162 | 0.390 |
Why?
|
Carcinoma, Renal Cell | 6 | 2024 | 3164 | 0.360 |
Why?
|
MAP Kinase Signaling System | 1 | 2017 | 1486 | 0.350 |
Why?
|
Kidney Neoplasms | 6 | 2024 | 4249 | 0.330 |
Why?
|
Neoplasm Staging | 6 | 2022 | 11121 | 0.290 |
Why?
|
Prognosis | 13 | 2024 | 29625 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 11742 | 0.270 |
Why?
|
GTP Phosphohydrolases | 2 | 2021 | 517 | 0.260 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5789 | 0.260 |
Why?
|
Protein Kinase Inhibitors | 7 | 2022 | 5671 | 0.250 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2023 | 782 | 0.250 |
Why?
|
Indoles | 2 | 2023 | 1833 | 0.220 |
Why?
|
Survival Rate | 7 | 2021 | 12725 | 0.220 |
Why?
|
Mutation | 6 | 2022 | 30052 | 0.190 |
Why?
|
Signal Transduction | 3 | 2019 | 23445 | 0.170 |
Why?
|
Retrospective Studies | 14 | 2024 | 80636 | 0.170 |
Why?
|
Ureteral Neoplasms | 1 | 2020 | 106 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2023 | 3492 | 0.160 |
Why?
|
Pyrrolidines | 1 | 2020 | 338 | 0.150 |
Why?
|
Oncolytic Viruses | 1 | 2022 | 344 | 0.150 |
Why?
|
Quinolines | 1 | 2023 | 764 | 0.150 |
Why?
|
Humans | 40 | 2024 | 761504 | 0.140 |
Why?
|
Single-Blind Method | 1 | 2021 | 1572 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2018 | 727 | 0.140 |
Why?
|
Oncolytic Virotherapy | 1 | 2022 | 516 | 0.130 |
Why?
|
Immunotherapy | 5 | 2023 | 4652 | 0.130 |
Why?
|
Testicular Neoplasms | 1 | 2022 | 799 | 0.130 |
Why?
|
Urologic Neoplasms | 1 | 2019 | 314 | 0.120 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2017 | 641 | 0.120 |
Why?
|
Tumor Burden | 1 | 2021 | 1893 | 0.120 |
Why?
|
Cyclic AMP | 1 | 2019 | 1463 | 0.120 |
Why?
|
Angiogenesis Inhibitors | 2 | 2022 | 2047 | 0.120 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2018 | 517 | 0.110 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 1222 | 0.110 |
Why?
|
Time Factors | 5 | 2022 | 39967 | 0.110 |
Why?
|
Pyrroles | 1 | 2020 | 1125 | 0.110 |
Why?
|
Deoxycytidine | 1 | 2018 | 877 | 0.110 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39106 | 0.110 |
Why?
|
Antineoplastic Agents | 4 | 2021 | 13639 | 0.110 |
Why?
|
Combined Modality Therapy | 2 | 2022 | 8529 | 0.110 |
Why?
|
Aged | 15 | 2021 | 169289 | 0.100 |
Why?
|
Membrane Proteins | 2 | 2021 | 7856 | 0.100 |
Why?
|
Esophageal Neoplasms | 1 | 2023 | 1654 | 0.100 |
Why?
|
Middle Aged | 17 | 2023 | 220895 | 0.100 |
Why?
|
Cisplatin | 1 | 2018 | 1651 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2022 | 2057 | 0.100 |
Why?
|
Bone Neoplasms | 1 | 2024 | 2529 | 0.100 |
Why?
|
Radiosurgery | 1 | 2021 | 1342 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2023 | 2223 | 0.090 |
Why?
|
Brain Neoplasms | 2 | 2022 | 9031 | 0.090 |
Why?
|
Adult | 14 | 2021 | 221177 | 0.090 |
Why?
|
Male | 19 | 2023 | 360804 | 0.090 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2020 | 0.080 |
Why?
|
China | 3 | 2021 | 2369 | 0.080 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3877 | 0.080 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4111 | 0.080 |
Why?
|
Female | 18 | 2022 | 392644 | 0.080 |
Why?
|
Boston | 1 | 2021 | 9326 | 0.070 |
Why?
|
Disease Progression | 2 | 2021 | 13506 | 0.070 |
Why?
|
Immunoglobulin G | 1 | 2019 | 4544 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9177 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15266 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6484 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2021 | 58976 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 9280 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9469 | 0.050 |
Why?
|
MicroRNAs | 1 | 2019 | 3816 | 0.050 |
Why?
|
Lymphatic Metastasis | 2 | 2020 | 2915 | 0.050 |
Why?
|
Leukopenia | 1 | 2020 | 213 | 0.040 |
Why?
|
Young Adult | 3 | 2021 | 59243 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 23995 | 0.040 |
Why?
|
Survival Analysis | 2 | 2022 | 10090 | 0.040 |
Why?
|
Nails | 1 | 2020 | 296 | 0.040 |
Why?
|
Calcium-Binding Proteins | 1 | 2023 | 1069 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 794 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13380 | 0.040 |
Why?
|
Cyclin D1 | 1 | 2019 | 451 | 0.040 |
Why?
|
Drug Synergism | 1 | 2021 | 1755 | 0.040 |
Why?
|
Risk Factors | 2 | 2022 | 74206 | 0.040 |
Why?
|
Proteinuria | 1 | 2020 | 607 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 2022 | 1393 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 698 | 0.030 |
Why?
|
Foot | 1 | 2020 | 575 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2019 | 749 | 0.030 |
Why?
|
Protein Kinases | 1 | 2023 | 1608 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2020 | 732 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2021 | 64680 | 0.030 |
Why?
|
Hand | 1 | 2020 | 902 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2219 | 0.030 |
Why?
|
Gene Amplification | 1 | 2018 | 1089 | 0.030 |
Why?
|
Gene Dosage | 1 | 2017 | 1217 | 0.030 |
Why?
|
Paclitaxel | 1 | 2021 | 1732 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2020 | 1141 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4853 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2020 | 1376 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6132 | 0.020 |
Why?
|
Prospective Studies | 3 | 2022 | 54425 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2022 | 3466 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3595 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4352 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5486 | 0.020 |
Why?
|
Proteins | 1 | 2023 | 6032 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2018 | 4915 | 0.020 |
Why?
|
Sirolimus | 1 | 2014 | 1533 | 0.020 |
Why?
|
Adolescent | 3 | 2021 | 88319 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6766 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10766 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2014 | 2057 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 4580 | 0.020 |
Why?
|
Incidence | 1 | 2022 | 21353 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6814 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12463 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9420 | 0.010 |
Why?
|
Mice | 2 | 2019 | 81525 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16981 | 0.010 |
Why?
|
Animals | 2 | 2019 | 168459 | 0.010 |
Why?
|
Child | 1 | 2018 | 80153 | 0.010 |
Why?
|
Concepts
(127)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_